ArticleInfection and drug resistance2026
Dermatopathic Lymphadenopathy with
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dermatopathic lymphadenitis (DL) is a rare reactive lymphoproliferative disorder often secondary to chronic dermatological conditions, which can be clinically misdiagnosed as lymphoma and other malignant diseases. Anti-IFN-γ autoantibodies can predispose adults to rare opportunistic infections, but reports of DL combined with Case Description: A 56-year-old male patient presented with recurrent rashes, significant itching, desquamation, and multiple lymph node enlargements, accompanied by fever, night sweats, and weight loss. Lymph node biopsy revealed dermatopathic changes and reactive lymphoid hyperplasia. TCR and IGH gene rearrangements demonstrated negative results, and no abnormal phenotypes were detected by peripheral blood flow cytometry. Hematological and immunological tests revealed elevated white blood cells, neutrophils, and IgE levels, along with positive anti-IFN-γ autoantibodies (29.22 ng/mL). NGS testing of secretions from the ulcerated skin area of the parotid gland confirmed TM infection. The diagnosis was determined as anti-IFN-γ autoantibody-mediated TM infection, complicated by DL and reactive lymphoid hyperplasia. Antifungal therapy with amphotericin B combined with voriconazole was administered, along with symptomatic and immunomodulatory treatments. Lymph node enlargement and systemic symptoms significantly improved, and the rash completely resolved. Conclusion: This case suggests that in adult patients with diffuse skin lesions and systemic inflammatory reactions, if accompanied by multiple lymph node enlargements and pathological findings of cutaneous lymphadenitis, potential immune deficiencies related to anti-IFN-γ autoantibodies should be considered. For adults with unexplained lymphadenopathy accompanied by fungal infection, testing for anti-interferon-γ autoantibodies is recommended to identify potential underlying immune abnormalities and to inform subsequent individualized immunological assessment and therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.